Overview

Tepotinib Hepatic Impairment Trial

Status:
Completed
Trial end date:
2019-02-05
Target enrollment:
Participant gender:
Summary
The study will investigate the effect of various degrees of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of tepotinib.
Phase:
Phase 1
Details
Lead Sponsor:
EMD Serono Research & Development Institute, Inc.
Collaborators:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Tepotinib